Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that using very-low-dose oral minoxidil (0.25 mg/d) led to improvement or stabilization of hair parameters in 40% to 60% of men with androgenetic alopecia, although results were not statistically significant for the overall group.

In male pattern hair loss, this study found that finasteride 1 mg daily significantly slowed hair loss and increased hair growth over two years compared to placebo.

In this case report, a male patient's semen parameters improved after discontinuing a 1-mg dose of finasteride, suggesting that stopping the medication may benefit infertile men with previous sperm production issues.

This study found that in Japanese male patients with androgenetic alopecia, dutasteride 0.5 mg daily over 52 weeks was associated with improvements in hair growth and appearance, with reported adverse events mostly mild.

In this correspondence, researchers reported that very-low-dose oral minoxidil (0.25 mg/d) showed some effectiveness in stabilizing trichoscopic parameters in male androgenetic alopecia. However, their analysis suggests that higher doses (2.5–5 mg/d) may lead to better clinical responses with similar rates of adverse events.

In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.

This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.

In this study, topical minoxidil 7% with dutasteride 0.5 mg showed higher efficacy but more adverse effects compared to minoxidil 7% with finasteride 1 mg for treating androgenetic alopecia.

This study found that increased serum testosterone and dehydroepiandrosterone sulphate levels may serve as diagnostic markers for seborrheic meibomian gland dysfunction in both genders.

This pharmacovigilance study found that certain systemic medications, including finasteride, bortezomib, and dupilumab, were disproportionately reported in association with eyelid disorders like blepharitis, meibomian gland dysfunction, and chalazia, suggesting these drugs may contribute to these conditions though benefits might still outweigh the risks.

This review highlights that Cyproterone acetate combined with ethinylestradiol is highly effective for treating severe acne and hirsutism in women with hyperandrogenism, and it also provides benefits for cycle control and mood improvement, according to the analysis of 78 studies.

This study observed that hepatotoxicity is a rare but possible event in hyperandrogenic young females treated with low- and ultralow-dose flutamide, regardless of dose or oral contraceptive use.

This study aimed to identify reliable predictors for the effectiveness of metformin therapy in weight loss and reduction of plasma androgen levels in PCOS women, highlighting the unpredictability of response to treatment.

This study found that combining low-dose spironolactone with metformin provided greater clinical benefits and improved treatment compliance in women with PCOS compared to either drug alone.

This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.

This case study documents a potential relationship between venlafaxine use and the onset of paranoia, which resolved upon discontinuation and recurred when reintroduced.

This article details various skin and oral lesions through illustrative figures but does not present new research results.

This study found that both oral minoxidil and topical 5% minoxidil were effective and safe for treating female pattern hair loss over 24 weeks, with oral administration not being inferior to topical treatment.

Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.

This study found that combined intense pulsed light and low-level light therapy significantly improved ocular surface outcomes and quality of life for patients with meibomian gland dysfunction and dry eye disease.

This study used in vivo confocal microscopy and a ResNet34 deep learning model to classify meibomian gland images with an AUROC greater than 0.95, indicating its potential for automatic diagnosis and screening of meibomian gland dysfunction.

This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.

This article discusses frontal fibrosing alopecia, noting potential connections to lichen planopilaris, but reports no new clinical findings.

This study observed that treatment with spironolactone significantly improved pain, inflammatory lesion count, and HS-PGA scores among female patients with hidradenitis suppurativa, suggesting its potential as an effective treatment option, even at lower doses, despite no change in Hurley stage or fistula count.

This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea.

In this study, pioglitazone treatment in patients with lichen planopilaris showed limited success, with significant improvement seen in only a minority of cases.

This study found that using an oral contraceptive with bicalutamide significantly reduced hirsutism in women with PCOS compared to an oral contraceptive alone, although it increased total cholesterol and LDL levels.

In this study, combination therapy with cyclosporine and PUVA for severe alopecia areata resulted in a majority of patients showing only fair to poor responses, though some improvements were noted.

This study found that a series of three monthly courses of medium-dose prednisolone pulse therapy was effective and well tolerated in most patients with active, multifocal alopecia areata but not in those with totalis/universalis.

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.